Integrated Pharmaceuticals Inc - Notification that Quarterly Report will be submitted late (NT 10-Q)
2007年11月15日 - 3:54AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
One)
o
Form
10-K
o
Form
20-F
o
Form
11-K
x
Form
10-Q
o
Form
10-D
o
Form
N-SAR
o
Form N-CSR
For
Period Ended:
September 30, 2007
o
Transition
Report on Form
10-K
o
Transition
Report on Form
20-F
o
Transition
Report on Form
11-K
o
Transition
Report on Form
10-Q
o
Transition
Report on Form
N-SAR
For
the
Transition Period Ended:
Read
Instruction (on back page) Before Preparing Form. Please Print or
Type.
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If
the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART
I
—
REGISTRANT INFORMATION
Integrated
Pharmaceuticals, Inc.
Full Name of
Registrant
|
N/A
Former Name if
Applicable
|
310 Authority Drive
Address of Principal Executive Office (Street
and
Number)
|
Fitchburg, MA 01420-6047
City, State and Zip
Code
|
PART
II
—
RULES
12b-25(b) AND (c)
If
the
subject report could not be filed without unreasonable effort or expense and
the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could
not
be eliminated without unreasonable effort or expense;
|
|
|
|
x
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form
10-K,
Form 20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof, will
be
filed on or before the fifteenth calendar day following the prescribed
due
date; or the subject quarterly report or transition report on Form
10-Q,
or portion thereof, will be filed on or before the fifth calendar day
following the prescribed due date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
PART
III
—
NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D,
N-SAR, N-CSR, or the transition report, or portion thereof, could not be filed
within the prescribed time period.
The
Registrant is not able to file its Form 10-QSB for the period ended September
30, 2007 on the date required. The Registrant is in the process of
preparing and reviewing the financial information and compiling and
disseminating the information required to be
included
in the Form 10-QSB for the period ended September 30, 2007, as well as the
completion of the required review of the Company's financial information,
none
of which could be completed by the date required without incurring undue
hardship and expense. The Registrant expects to file its Form 10-QSB
within the 5 calendar days provided by this extension.
PART
IV
—
OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this
notification
Peter
Featherston
(978) 696-0020
(Name)
(Area
Code) (Telephone Number)
(2)
Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s).
x
Yes
o
No
(3)
Is it anticipated that any significant change in results of operations from
the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the
subject
report or portion thereof?
o
Yes
x
No
If
so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Integrated Pharmaceuticals,
Inc.
(Name of
Registrant as Specified in Charter)
In
accordance with section 13 or 15(d) of the Exchange Act, the registrant has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
November 14, 2007
By:
/s/
Peter
Featherston
Peter
Featherston
Chief
Executive Officer
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any
other
duly authorized representative. The name and title of the person signing the
form shall be typed or printed beneath the signature. If the statement is signed
on behalf of the registrant by an authorized representative (other than an
executive officer), evidence of the representative’s authority to sign on behalf
of the registrant shall be filed with the form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See
18 U.S.C. 1001).
Integrated Pharmaceuticals (CE) (USOTC:INTP)
過去 株価チャート
から 5 2024 まで 6 2024
Integrated Pharmaceuticals (CE) (USOTC:INTP)
過去 株価チャート
から 6 2023 まで 6 2024